Phase 3 Dermatitis, Atopic trials in Bulgaria: Trial Insights

Filters: Condition: Dermatitis, Atopic Phase: Phase 3 Country / region: Bulgaria Clear all

21 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2013	1
2014	1
2018	7
2019	2
2020	2
2022	1
2023	3
2024	4

Trials by status
Category	Trials
Completed	18
Active, not recruiting	2
Terminated	1

Top lead sponsors
Category	Trials
Pfizer	5
AbbVie	4
Sanofi	3
Amgen	2
Eli Lilly and Company	2
Incyte Corporation	2
Regeneron Pharmaceuticals	2
Galderma R&D	1

Top conditions
Category	Trials
Dermatitis, Atopic	21
Eczema	11
Dermatitis	4
Skin Diseases	4
Genetic Diseases, Inborn	2
Hypersensitivity	2
Hypersensitivity, Immediate	2
Immune System Diseases	2
Pruritus	2
Skin Diseases, Eczematous	2

Trials

Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Phase 3Active, not recruitingAbbVieStarted 2024
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06407934Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis NCT06238817Phase 3CompletedIncyte CorporationStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids NCT06224348Phase 3CompletedSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) NCT06181435Phase 3CompletedSanofiStarted 2023
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05882877Phase 3TerminatedAmgenStarted 2023
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05724199Phase 3CompletedAmgenStarted 2023
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis NCT05601882Phase 3CompletedAbbVieStarted 2022
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) NCT04392154Phase 3CompletedEli Lilly and CompanyStarted 2020
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy NCT04345367Phase 3CompletedPfizerStarted 2020
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis NCT04178967Phase 3CompletedEli Lilly and CompanyStarted 2019
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis NCT03989349Phase 3CompletedGalderma R&DStarted 2019
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis NCT03745651Phase 3CompletedIncyte CorporationStarted 2018
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy NCT03720470Phase 3CompletedPfizerStarted 2018
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) NCT03569293Phase 3CompletedAbbVieStarted 2018
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) NCT03607422Phase 3CompletedAbbVieStarted 2018
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis NCT03575871Phase 3CompletedPfizerStarted 2018
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects NCT03627767Phase 3CompletedPfizerStarted 2018
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis NCT03422822Phase 3CompletedPfizerStarted 2018
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT02277743Phase 3CompletedRegeneron PharmaceuticalsStarted 2014
Open-label Study of Dupilumab in Patients With Atopic Dermatitis NCT01949311Phase 3CompletedRegeneron PharmaceuticalsStarted 2013

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Status changeRecruiting to Active, not recruitingOctober 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory